Live Breaking News & Updates on Pilar Manzano

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi that endangers almost 70 million people worldwide. The only two drugs that are currently approved for its treatment, benznidazole and nifurtimox, have controversial efficacy in adults and restricting safety issues, leaving thousands of patients without a suitable treatment. The neglect of Chagas disease is further illustrated by the lack of a robust and diverse drug discovery and development portfolio of new chemical entities, and it is of paramount importance to build a strong research and development network for antichagasic drugs. Focusing on drug discovery programs led by scientists based in Latin America, the main endemic region for this disease, we discuss herein what has been published in the last decade in terms of identification of new antiparasitic drugs to treat Chagas disease, shining a spotlight on the origin, chemical diversity, level of characterization of hits, and strategi ....

United States , El Salvador , Pilar Manzano , Fonseca Murta , Oswaldo Cruz , Van Huijsduijnen , Stardrop Hann , Garcia Bournissen , Van Voorhis , Benznidazole Monotherapy , Acta Tropica , Properties Of Approved Oral Drugs , Types Of Drug Discovery Campaign , Research Methodology , Chagas Disease Drug Development , Devaluation Of Properties , Optibrium Ltd , Molecule Properties For Medicinal Chemists , Chemical Properties To Desired Product Profile , American Health Organization , Drug Development For Chagas Disease , Pan American Health Organization , Neglected Diseases , Latin America , Latin American , Initial Chemical ,